Back to News
Market Impact: 0.2
JP Morgan Upgrades Pacira BioSciences to Neutral from Underweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 8, 2026, JPMorgan upgraded its outlook on Pacira BioSciences from Underweight to Neutral, according to Fintel. The article excerpt provides no rationale, price target, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
PCRX0.35
More News
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- Hexagon jumps 3% as J.P. Morgan sees earnings upside from recovering demand
- Cramer’s week ahead: Earnings kick off as banks and chipmakers face big tests
- JPMorgan downgrades DuPont stock rating on recovery outlook
- Jim Cramer's top 10 things to watch in the stock market Friday
- Crown Holdings Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect
- Fintool Alternatives After the Microsoft Acquisition